Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.61 |
| ▸ | MAPT | P10636 | 6/20 | 0.61 |
| ▸ | HPGD | P15428 | 6/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.61 |
| ▸ | TP53 | P04637 | 4/20 | 0.61 |
| ▸ | NPC1 | O15118 | 4/20 | 0.61 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.46 |
| ▸ | CCR1 | P32246 | 2/20 | 0.46 |
| ▸ | CCR5 | P51681 | 2/20 | 0.46 |
| ▸ | CCR8 | P51685 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.46 |
| ▸ | ALPL | P05186 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4197892 | 0.80 | GRM5 (0.60) | KDM4ESMN1; SMN2ALDH1A1MAPTHPGD | |
| SCHEMBL4431583 | 0.80 | ENPP1 (0.60) | KDM4ESMN1; SMN2ALDH1A1MAPTHPGD | |
| SCHEMBL4179013 | 0.79 | GRM5 (0.49) | KDM4ESMN1; SMN2ALDH1A1MAPTHPGD | |
| SCHEMBL4189978 | 0.79 | GRM5 (0.63) | KDM4ESMN1; SMN2ALDH1A1MAPTHPGD | |
| SCHEMBL31473547 | 0.78 | KDM4E (0.63) | KDM4ESMN1; SMN2ALDH1A1MAPTHPGD | |
| SCHEMBL57525 | 0.78 | KDM4E (0.63) | KDM4ESMN1; SMN2ALDH1A1MAPTHPGD | |
| SCHEMBL29484714 | 0.78 | KDM4E (0.63) | KDM4ESMN1; SMN2ALDH1A1MAPTHPGD | |
| SCHEMBL31607260 | 0.78 | KDM4E (0.63) | KDM4ESMN1; SMN2ALDH1A1MAPTHPGD | |
| SCHEMBL30414741 | 0.78 | ENPP1 (0.49) | KDM4ESMN1; SMN2ALDH1A1MAPTHPGD | |
| SCHEMBL30414742 | 0.78 | ENPP1 (0.49) | KDM4ESMN1; SMN2ALDH1A1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054491-A1 | Use | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | claimed |
| EP-1896011-A1 | NEW USE | AstraZeneca AB (SE) | 2008-03-12 | — | — | EP | claimed |
| US-20070010553-A1 | New use | ASTRAZENECA AB (SE) | 2007-01-11 | — | — | US | claimed |
| WO-2007001973-A1 | NEW USE | ASTRAZENECA AB (SE) | 2007-01-04 | — | — | WO | claimed |
| EP-1582519-A2 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | NPS PHARMACEUTICALS, INC. (US) | 2005-10-05 | — | — | EP | claimed |
| WO-2005060961-A2 | TREATMENT OF TRANSIENT LOWER ESOPHAGEAL SPHINCTER RELAXATIONS (TLESRS) AND GASTRO-ESOPHAGEAL REFLUX DISEASE (GERD) | ASTRAZENECA AB (US) | 2005-07-07 | — | — | WO | claimed |
| WO-2005060971-A1 | TREATMENT OF REFLUX-RELATED DISEASES | ASTRAZENECA AB (SE) | 2005-07-07 | — | — | WO | claimed |
| US-20030055085-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2003-03-20 | — | — | US | claimed |
| EP-1210344-A1 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | NPS PHARMACEUTICALS, INC. (US) | 2002-06-05 | — | — | EP | claimed |
| WO-2001012627-A1 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | NPS PHARMACEUTICALS, INC. (US) | 2001-02-22 | — | — | WO | claimed |
| US-20090054491-A1 | Use | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | US | disclosed |
| EP-1896011-A1 | NEW USE | AstraZeneca AB (SE) | 2008-03-12 | — | — | EP | disclosed |
| US-20070010553-A1 | New use | ASTRAZENECA AB (SE) | 2007-01-11 | — | — | US | disclosed |
| WO-2007001973-A1 | NEW USE | ASTRAZENECA AB (SE) | 2007-01-04 | — | — | WO | disclosed |
| US-7112595-B2 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | NPS PHARMACEUTICALS, INC. (US) | 2006-09-26 | — | — | US | disclosed |
| US-20030055085-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | ASTRAZENECA AB (SE) | 2003-03-20 | — | — | US | disclosed |
| WO-2002068417-A3 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | SLASSI ABDELMALIK (CA) | 2002-11-14 | — | — | WO | disclosed |
| WO-2002068417-A2 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | NPS PHARMACEUTICALS, INC. (US) | 2002-09-06 | — | — | WO | disclosed |
| EP-1210344-A1 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | NPS PHARMACEUTICALS, INC. (US) | 2002-06-05 | — | — | EP | disclosed |
| WO-2001012627-A1 | HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS | NPS PHARMACEUTICALS, INC. (US) | 2001-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054491-A1 | Use | FABP6, SLC10A2, GPR119 | KDM4E 3046/4885SMN1; SMN2 2639/4885ALDH1A1 276/4885 |
| US-20030055085-A1 | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists | GRM2, GRIN2A, GRM1 | KDM4E 3972/4885SMN1; SMN2 1279/4885ALDH1A1 3466/4885 |
| US-20070010553-A1 | New use | GRM5, GRM3, GRM1 | KDM4E 3765/4885SMN1; SMN2 3124/4885ALDH1A1 3980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.